Abstracts tagged "NLRP3 inflammasome and New Therapeutics"

Abstract Number: 1237 • 2019 ACR/ARP Annual Meeting
Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
Viola Kluck¹, Tim Jansen ², Matthijs Janssen ³, Isak Tengensdal ⁴, Kiki Schraa ⁵, Maartje Cleophas ⁵, Damaris Skouras ⁶, Carlo Marchetti ⁴, Charles Dinarello ⁷ and Leo Joosten ⁸, ¹Radboudumc, Nijmegen, Netherlands, ²Viecuri MC, Venlo, Netherlands, ³VieCuri Medical Center, Venlo, Netherlands, ⁴University of Colorado Denver, Denver, CO, ⁵Radboudumc, Nijmegen, ⁶Olatec Therapeutics LLC, New York, NY, ⁷University of Colorado Denver, Aurora, CO, ⁸Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Gout flares are characteristically mediated by the pro-inflammatory cytokine interleukin (IL)-1β. Uptake of monosodium urate (MSU) crystals by macrophages activates the nucleotide-binding domain and…
Abstract Number: 2838 • 2019 ACR/ARP Annual Meeting
The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout
Tim Jansen¹, Viola Kluck ², Matthijs Janssen ³, Antoaneta Comarniceanu ³, Monique Efdé ³, Curtis Scribner ⁴, Damaris Skouras ⁵, Charles Dinarello ⁶ and Leo Joosten ⁷, ¹Viecuri MC, Venlo, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³VieCuri Medical Center, Venlo, Netherlands, ⁴Olatec Therapeutics LLC, New York, ⁵Olatec Therapeutics LLC, New York, NY, ⁶University of Colorado Denver, Aurora, CO, ⁷Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Acute gout is a severe debilitating type of arthritis that is treated in the acute phase with potent anti-inflammatory drugs. To date, prednisolone, colchicine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].